Cover Image

Pharmacokinetics of bempedoic acid in patients with renal impairment

Abstract Bempedoic acid is an ATP citrate lyase inhibitor approved for the treatment of hypercholesterolemia. The objective of this phase I study was to assess the pharmacokinetics (PKs) and safety of bempedoic acid in 24 subjects with normal renal function or mild, moderate, or severe renal impairm...

Full description

Saved in:

Bibliographic Details
Main Authors:	Benny M. Amore (Author), William J. Sasiela (Author), Daniel K. Ries (Author), Perry Tresh (Author), Maurice G. Emery (Author)
Format:	Book
Published:	Wiley, 2022-03-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Absence of effect of steady state bempedoic acid on cardiac repolarization: Results of a thorough QT/QTc study in healthy volunteers
by: Benny M. Amore, et al.
Published: (2021)

Physiologically Based Pharmacokinetic Model Development and Verification for Bioequivalence Testing of Bempedoic Acid Oral Suspension and Reference Tablet Formulation
by: Benny M. Amore, et al.
Published: (2023)

Bempedoic Acid in Secondary Prevention
by: Idine Mousavi, et al.
Published: (2024)

Bempedoic acid for the treatment of dyslipidemia
by: Joel C Marrs, et al.
Published: (2020)

The Pathogenetic Basis of the Action of Bempedoic Acid
by: A. S. Petrosyan, et al.
Published: (2023)

Bempedoic Acid for Heterozygous Familial Hypercholesterolemia: From Bench to Bedside
by: Agarwala A, et al.
Published: (2021)

Bempedoic acid - new agent in hiperlipidemia treatment - literature review
by: Agata Frańczuk, et al.
Published: (2024)

Bempedoic Acid: Safety and Efficiacy of a New Lipid-Lowering Agent
by: I. A. Mazerkina, et al.
Published: (2023)

Bempedoic Acid: A Novel Approach in Managing Dyslipidemia and Reducing Cardiovascular Risk
by: Łukasz Wołowiec, et al.
Published: (2024)

Pharmacokinetic profile of defibrotide in patients with renal impairment
by: Tocchetti P, et al.
Published: (2016)

Bempedoic Acid and Statins in Lipid-Lowering Strategy: Which Came First, the Egg or the Chicken?
by: Francesco Natale, et al.
Published: (2023)

Mechanism of bempedoic acid induced cholelithiasis: A role for statins to limit this adverse effect?
by: Nicola Ferri, et al.
Published: (2023)

Effect of Renal Impairment on the Pharmacokinetics of Memantine
by: Takashi Moritoyo, et al.
Published: (2012)

Stability indicating RP-UPLC method for simultaneous quantification of bempedoic acid and ezetimibe in bulk and pharmaceutical formulations
by: Uma Sai Teja Yarra, et al.
Published: (2021)

A UK multicentre audit of the management of patients with primary hypercholesterolaemia or mixed dyslipidaemia with bempedoic acid against published lipid-lowering treatment targets
by: Sudarshan Ramachandran, et al.
Published: (2024)

Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials
by: Xiang Zhao, et al.
Published: (2020)

Characterization of novel stress degradation products of Bempedoic acid and Ezetimibe using UPLC-MS/MS: development and validation of stability-indicating UPLC method
by: Anuradha Vejendla, et al.
Published: (2021)

Bempedoic Acid, the First-in-Class Oral ATP Citrate Lyase Inhibitor with Hypocholesterolemic Activity: Clinical Pharmacology and Drug-Drug Interactions
by: Nicola Ferri, et al.
Published: (2024)

Population Pharmacokinetic/Pharmacodynamic Modelling of Daptomycin for Schedule Optimization in Patients with Renal Impairment
by: Teresa García-Martínez, et al.
Published: (2022)

Effect of severe renal impairment on pharmacokinetics, safety, and tolerability of lemborexant
by: Ishani Landry, et al.
Published: (2021)

Physiologically based pharmacokinetic modeling of daptomycin dose optimization in pediatric patients with renal impairment
by: Lingling Ye, et al.
Published: (2022)

Effect of bempedoic acid plus ezetimibe fixed-dose combination vs ezetimibe or placebo on low-density lipoprotein cholesterol in patients with type 2 diabetes and hypercholesterolemia not treated with statins
by: Harold E. Bays, et al.
Published: (2021)

A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment
by: Karthick Vishwanathan, et al.
Published: (2020)

Population Pharmacokinetics and Model-Based Dose Optimization of Vancomycin in Sudanese Adult Patients with Renal Impairment
by: Ahmed KA, et al.
Published: (2024)

A Comprehensive Physiologically Based Pharmacokinetic Model for Predicting Vildagliptin Pharmacokinetics: Insights into Dosing in Renal Impairment
by: Mahnoor Pasha, et al.
Published: (2024)

Population pharmacokinetics of pomalidomide in patients with relapsed or refractory multiple myeloma with various degrees of impaired renal function
by: Li Y, et al.
Published: (2017)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
by: Benjamin Berger, et al.
Published: (2021)

Simulation-Based Analysis of the Impact of Renal Impairment on the Pharmacokinetics of Highly Metabolized Compounds
by: Kristin E. Follman, et al.
Published: (2019)

Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes
by: Yoshiko Tomita, et al.
Published: (2022)

Pharmacokinetics, pharmacodynamics, and safety of ciprofol emulsion in Chinese subjects with normal or impaired renal function
by: Jun Tao, et al.
Published: (2023)

Pharmacokinetics of conivaptan use in patients with severe hepatic impairment
by: Marbury T, et al.
Published: (2017)

Physiologically based pharmacokinetic modeling of candesartan to predict the exposure in hepatic and renal impairment and elderly populations
by: Lingfeng Guo, et al.
Published: (2023)

Physiologically based pharmacokinetic modeling of levetiracetam to predict the exposure in hepatic and renal impairment and elderly populations
by: Chaozhuang Shen, et al.
Published: (2023)

Effect of hepatic and renal impairment on the pharmacokinetics of olanzapine and samidorphan given in combination as a bilayer tablet
by: Sun L, et al.
Published: (2019)

Effect of renal impairment on the pharmacokinetics and safety of dorzagliatin, a novel dual‐acting glucokinase activator
by: Jia Miao, et al.
Published: (2022)

Application of Physiologically Based Pharmacokinetic Model to Delineate the Impact of Aging and Renal Impairment on Ceftazidime Clearance
by: Khaled Abduljalil, et al.
Published: (2024)

Population Pharmacokinetics of Mycophenolic Acid in Renal Transplant Patients: A Comparison of the Early and Stable Posttransplant Stages
by: Peile Wang, et al.
Published: (2022)

Effect of renal impairment on the pharmacokinetics of prucalopride: a single- dose open-label Phase I study
by: Smith WB, et al.
Published: (2012)

Pharmacokinetics, Safety, and Tolerability of Solifenacin in Patients With Renal Insufficiency
by: Ronald A. Smulders, et al.
Published: (2007)

ATP citrate lyase inhibitor Bempedoic Acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score
by: K.V. Sanjay, et al.
Published: (2021)